PRESS COVERAGE

 

Brinson Patrick Press Coverage

09.02.2013 – Growth Capital Investor
ATM Deals Grow While Registered Directs and CMPOs Stagnate
The number of ATM offerings continues to grow

04.24.2013 – Seeking Alpha
An Industry Outlook with Analyst Vernon Bernardino
Brinson Patrick research analyst provides an outlook on the biotech industry

02.27.2013 – Reuters
Bank Fees Drop
U.S. companies change way they sell stock

02.04.2013 – Growth Capital Investor
ATM Offerings and Equity Lines
Three Differences Issuers Need to Understand

12.20.2012 – The Life Sciences Report
Four Biotech Names with Major Market Potential
Michael Higgins uses his experience as a drug marketer with big pharma to identify investment opportunities in companies with new drugs that address unmet needs

12.17.2012 – BioWorld Insight
Popularity of ATMs Continues to Grow
Use of ATM offerings by life sciences companies reached a record high in the third quarter

10.01.2012 – Growth Capital Investor
ATMs On the Rise
The rapid growth of ATM issuance is clear evidence that management teams consider ATMs a great idea

10.01.2012 – Genetic Engineering & Biotechnology News
Advice to Biofirms: Be Prepared, Plan Ahead
Article features Robert E. Hoffman, CFO of Arena Pharmaceuticals (NASDAQ: ARNA)

09.25.2012 – MedCity News
ATM Offerings Provide Alternative Approach to Raising Capital
Article features Christopher J. Reinhard, CEO and Chairman of Cardium Therapeutics (NYSE MKT: CXM)

08.20.2012 – BioWorld Insight
ATM Financing Provides Effective Access to Cash
Handy Tool for CFOs

08.01.2012 – Life Science Leader
Raising Life Sciences Capital: An Alternative Way
There are various strategies public life sciences companies use to raise equity capital

07.19.2012 – MedCity News
Common Misunderstandings of an Emerging Financing Vehicle: At-the-Market Offerings
Strategic CFOs in the life sciences industry are increasingly employing ATMs because they enable companies to better control the financing process and the relatively low cost compared to more traditional follow-on financing vehicles.

07.01.2012 – Genetic Engineering & Biotechnology News
Dispelling ATM Offering Myths
Better Control of Financing Process Enabled by Increasingly Popular At-the-Market Offerings

06.22.2012 – “The Pink Sheet” DAILY
Life Sciences Firms’ Use Of At-The-Market Financing Vehicle Rising
ATM transactions by U.S. life sciences firms totaled $90 million in the first quarter of 2012

04.09.2012 – San Diego Business Journal
More Biotech Firms Head to ATM for Cash
LIFE SCIENCES: New Financing Approach Is Gaining Attention

03.01.2012 – Genetic Engineering & Biotechnology News
Uncertainty & Cautious Optimism Define Last Year’s Performance
Highs and Lows Characterize 2011

01.15.2012 – Genetic Engineering & Biotechnology News
Shopping for Financing “At-the-Market”
Alternate Option May Offer Huge Savings, as Conventional Methods Can Cost 10x More

01.02.2012 – BioCentury
2012 Financial Markets Preview
By necessity, publicly held development stage biotechs have become increasingly sophisticated at accessing capital

An increasing number of companies are realizing that an ATM is an important tool in their overall financing strategy. Despite very volatile capital markets, companies are able to cost-effectively access capital through ATMs.”

Todd Wyche,
Brinson Patrick